RoslinCT
RoslinCT is a contract development and manufacturing organisation specialising in cell and gene therapies.
RoslinCT is no longer on the UK Home Office register of licensed sponsors (last seen 26 April 2026). Home Office figures released under the Freedom of Information Act show RoslinCT assigned 18 Certificates of Sponsorship in 2021–24 and 14 in 2025 for Skilled Worker and Global Business Mobility visas. We're showing 5 of their current openings.
Sponsor licence details
Sourced from the UK Home Office register of licensed sponsors.
Sponsorship history
Certificates of Sponsorship RoslinCT assigned each year, from Home Office figures released under the Freedom of Information Act.
Skilled Worker and Global Business Mobility routes. One certificate is assigned for each sponsored hire, visa extension or change of employer, so a person can be counted more than once. “1–5” is withheld by the Home Office; the 2025 figures list only sponsors with 5 or more (“—”). Matched to this employer by its name on the sponsor register. Sources: FOI 2025/12841 (2021–24), FOI2026/03501 (2025). Contains public sector information licensed under the Open Government Licence v3.0.
Licence timeline Pro
Every change we've seen on the Home Office register for RoslinCT, and what its recent adverts say about sponsorship.
See this employer's full licence history: when it was licensed, rating and route changes, and when it last offered sponsorship in an advert.
Unlock with ProAbout RoslinCT
RoslinCT is a contract development and manufacturing organisation (CDMO) that specialises in cell and gene therapies. The company supports therapy developers by translating complex biological processes into clinical and commercial-grade programs. It works across immunotherapies, gene-edited therapies, and stem cell platforms, with a particular focus on clinical-grade human pluripotent stem cells.
The organisation operates manufacturing suites to support both autologous and allogeneic manufacturing. Its services include process and analytical development, clinical and commercial manufacturing, cell banking, and regulatory compliance. In collaboration with Vertex Pharmaceuticals, the company helped develop the first CRISPR-edited cell therapy product for sickle cell disease and beta thalassemia.
Open roles
5 live positions matched to this sponsor licence.